Home > Oncology > ASCO 2021 > Breast Cancer > Dalpiciclib benefits patients with HR-positive, HER2-negative advanced breast cancer

Dalpiciclib benefits patients with HR-positive, HER2-negative advanced breast cancer

Presented By
Prof. Binghe Xu, Chinese Academy of Medical Sciences and Peking Union Medical College, China
Conference
ASCO 2021
Trial
Phase 3, DAWNA-1
First results of the DAWNA-1 trial showed increased progression-free survival in patients with HR-positive, HER2-negative advanced breast cancer who relapsed on endocrine therapy and who were treated with dalpiciclib, a new CDK4/6 inhibitor. For patients with HR-positive, HER2-negative advanced breast cancer, treatment with a CDK4/6 inhibitor combined with endocrine therapy is the standard of care, since it achieves a substantial progression-free benefit, significantly increases overall survival, and either maintains or improves quality of life [1]. Dalpiciclib is a novel CDK4/6 inhibitor that has demonstrated tolerability and preliminary anti-tumour activity in pre-treated HR-positive, HER2-negative advanced breast cancer [2]. DAWNA-1 (NCT03927456) is a randomised, phase 3 clinical trial evaluating the efficacy and sa...


Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on